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Primary Cardiac
Angiosarcoma with
Good Response
to Paclitaxel
To the Editor:
With reference to two recently pub-
lished reports on cardiac angiosarcoma1,2
wherein both patients had durable response
to concurrent chemoradiotherapy, we pres-
ent a case of right atrial metastatic angiosar-
coma who had a durable response to pacli-
taxel alone without radiotherapy.
A 48-year-old male developed
acute onset dyspnea; on evaluation, he had
hemorrhagic pericardial effusion with car-
diac tamponade. After urgent pericardio-
centesis, he was initially presumptively
treated with antitubercular therapy for 5
months. He required multiple pericardio-
centesis and underwent pleuropericardial
window surgery. Follow-up echocardio-
gram revealed right atrial tumor invading
the pericardium which was confirmed on
magnetic resonance imaging (Figure 1A)
and transesophageal echocardiogram.
Chest computerized tomogram addition-
ally revealed bilateral pleural effusion and
bilateral pulmonary metastases (Figure
1B). Tumor biopsy by percutaneous trans-
femoral route showed a malignant tumor
with vascular channels lined by atypical
endothelial cells (Figure 1C) which were
positive for CD31 and CD34. The patient
was then referred to our institute when he
was in Eastern Cooperative Oncology
Group performance status 2 with muffled
heart sounds. Biopsy and imaging were
reviewed and were compatible with met-
astatic right atrial angiosarcoma.
He was initially treated with pacli-
taxel 80 mg/m2 on day 1 and 8 every 3
weeks. After two cycles, his dyspnea im-
proved with complete resolution of right
atrial mass and reduction in number and
size of lung metastases. Because of good
tolerance, he received four additional cy-
cles of paclitaxel at 80 mg/m2 on days 1,
8, and 15 every 4 weeks. Computed to-
mography scan at the end of the treatment
showed complete resolution of right atrial
mass and lung metastasis (Figure 1D), and
the patient is now progression-free for 16
months.
Cardiac angiosarcoma is the most
common malignant tumor of heart, often
arising from right atrium; 80% of them
present with metastasis with median sur-
vival of 6 months. Nonmetastatic cardiac
angiosarcoma has been treated with radi-
cal surgery, adjuvant chemotherapy, and
radiotherapy. However, cardiac angio-
sarcomas are usually unresectable or
disseminated at presentation, making
radical excision difficult in most cases;
thus, palliation and prolongation of
survival remains the only option. Ifos-
famide, cyclophosphamide, dacarba-
zine, and doxorubicin mostly in com-
bination have been used in adjuvant or
metastatic setting, but there are no
clear guidelines as to which is the best
regimen.
In the two articles recently pub-
lished,1,2 it was interesting to note the
activity of taxanes. Concurrent radio-
therapy was used in both cases and in
the second case carboplatin was used
additionally. Docetaxel with radiother-
apy has resulted in good response with
a patient being alive at 1-year follow-
up.3 Herein, we present a patient who
had multiple lung metastasis and pleu-
ropericardial effusion who responded
very well to single agent paclitaxel
without radiotherapy.
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FIGURE 1. A, Magnetic resonance image of the heart at baseline showing a mass
lesion in the right atrium. B, Contrast-enhanced computed tomography (CT) scan
of the chest before treatment showing multiple lung metastasis in the right lower
lobe (red arrow). C, Hematoxylin & eosin section (400) of the biopsy specimen
showing ill-defined vascular channels lined by atypical endothelial cells. D, Con-
trast-enhanced CT scan of the chest posttreatment showing complete resolution of
lung metastasis.
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Paclitaxel has shown activity in
head and neck angiosarcomas apart
from angiosarcomas of other sites.4
There is one previous report of partial
response of cardiac angiosarcoma to sin-
gle agent paclitaxel with 9 months sur-
vival.5 Our case further substantiates the
excellent activity of taxanes in primary
cardiac angiosarcoma, and patients with
contraindication to radiotherapy may be
treated with paclitaxel alone with good
palliation.
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